The peripheral network between oxidative stress and inflammation in multiple sclerosis

European Journal of Inflammation

Volumn 12, Issue 2, 2014, Pages 351-363

  Gironi, Maira ^a   Borgiani, B ^a   Cursano, C ^b   Saresella, M ^c   Piancone, F ^c   Mariani, E ^b   Marventano, I ^c   Martinelli, V ^a   Comi, G ^a   Clerici, M ^c   Rovaris, M ^c   Furlan, R ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CAM   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Anti oxidized low density lipoproteins; Coenzyme Q10; Correlation; Immune phenotypic analysis; Multiple sclerosis; Oxidative stress biomarkers

Indexed keywords

ANTIBODY; AZATHIOPRINE; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GLATIRAMER; GLUTATHIONE; GLUTATHIONE DISULFIDE; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 4; INTERLEUKIN 6; LIPOCORTIN 5; MALONALDEHYDE; MYELIN BASIC PROTEIN; OXIDANT POWER ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; TH17 CELL; TH2 CELL;

EID: 84905825460     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1401200214     Document Type: Article

References (48)

1. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417(1):1-13.
2. Finkel T, Holbrook N. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408(6809):239-47.
3. Hildeman DA, Mitchell T, Kappler J, Marrack P. T cell apoptosis and reactive oxygen species. J Clin Invest 2003; 111(5):575-81. (Pubitemid 36278573)
4. Maemura K, Zheng Q, Wada T, et al. Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells. Immunol Cell Biol 2005; 83(4):336-43. (Pubitemid 41044610)
5. Henrotin Y, Bruckner P, Pujol J. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil 2003; 11(10):747-55. (Pubitemid 37184493)
6. Hultqvist M, Olsson L, Gelderman K, Holmdahl R. The protective role of ROS in autoimmune disease. Trends Immunol 2009; 30(5):201-8.
7. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251(3):261-8. (Pubitemid 38387142)
8. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra C, van der Valk P, de Vries, HE. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008; 45(12):1729-37.
9. Bizzozero O a, DeJesus G, Callahan K, Pastuszyn A. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res 2005; 81(5):687-95.
10. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999; 53(8):1876-9. (Pubitemid 29530374)
11. Fiorini A, Koudriavtseva T, Bucaj E, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 2013; 8(6):1-12.
12. Gironi M, Borgiani B, Mariani E, et al. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res Hindawi Publishing Corporation 2014; 2014:961863.
13. Di Penta A, Moreno B, Reix S, et al. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 2013; 8(2):e54722.
14. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134(Pt 7):1914-24.
15. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ Nature Publishing Group 2010; 17(7):1083-91.
16. Kalman B, Laitinen K, Komoly S. The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; 188(1-2):1-12. (Pubitemid 47095010)
17. Viglietta V, Baecher-Allan C, Weiner HL, Hafler D. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199(7):971-9. (Pubitemid 38481088)
18. Bar-Or A. Human immune studies in multiple sclerosis. Adv Neurol 2006; 98:91-109.
19. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 98(1-2):113-21. (Pubitemid 29015996)
20. Murzenok P, Matusevicius D, Freedman M. gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. Clin Immunol 2002; 103(3):309-16. (Pubitemid 34666755)
21. Benedetti B, Rovaris M, Rocca M. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 2009; 15(17):789-94.
22. Gironi M, Bianchi A, Russo A. Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis 2011; 8(3):129-37.
23. Mendes A, Sa M. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arq Neuropsiquiatr 2011; 69(3):536-43.
24. Chen M, Chen G, Deng S, Liu X, Hutton G, Hong J. IFN-β induces the proliferation of CD 4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 2012; 242(1-2):39-46.
25. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8(11):647-56.
26. Paap B, Hundeshagen A, Hecker M, Zettl U. An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients. Curr Pharm Des 2012; 18(29):4475-84.
27. Meuth S, Göbel K, Wiendl H. Immune therapy of multiple sclerosis: future strategies. Curr Pharm Des 2012; 18(29):4489-97.
28. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int 2013; 63(5):507-16.
29. Liu Z, Fan H, Jiang S. CD4(+) T-cell subsets in transplantation. Immunol Rev 2013; 252(1):183-91.
30. Kawamukai M. Biosynthesis and bioproduction of coenzyme Q10 by yeasts and other organisms. Biotechnol Appl Biochem 2009; 53(4):217-26.
31. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004; 1660(1-2):171-99. (Pubitemid 38125244)
32. Groneberg D, Kindermann B, Althammer M, Klapper M, Vormann J, Littarru G, Döring F. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int J Biochem Cell Biol 2005; 37(6):1208-18. (Pubitemid 40381197)
33. Marnett L. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999; 424(1-2).
34. Freeman G, Casasnovas J, Umetsu D, DeKruyff R. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235(1):172-89.
35. Zhu C, Anderson A, Schubart A. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6(12):1245-52. (Pubitemid 43045636)
36. Jovanović V, Abdul Aziz N, Lim YT, et al. Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus. PLoS One 2013; 8(2):e55639.
37. Shoji T, Nishizawa Y, Fukumoto M, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148(1):171-7.
38. Ding Z, Wang X, Schnackenberg L, et al. Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7 g. Int J Cardiol 2013; 168(2):137-85.
39. Wei D, Jia X, Liu Y, et al. Cathepsin L stimulates autophagy and inhibits apoptosis of ox-LDL-induced endothelial cells: potential role in atherosclerosis. Int J Mol Med 2013; 31(2):400-6.
40. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125(1):75-85. (Pubitemid 34084038)
41. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15(3):331-7.
42. Ferreira B, Mendes F, Osório N, Caseiro A, Gabriel A, Valado A. Glutathione in multiple sclerosis. Br J Biomed Sci 2013; 70(2):75-9.
43. Shechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer "if" but "how". J Pathol 2013; 229(2):332-46.
44. Ziegler-Heitbrock H. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 1995; 45(1):13-26.
45. Ren B, Malefyt DW, Haanen J, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174(4):915-24.
46. Ghasemi H, Ghazanfari T, Yaraee R, Owlia P, Hassan Z, Faghihzadeh S. Roles of IL-10 in ocular inflammations: a review. Ocul Immunol Inflamm 2012; 20(6):406-18.
47. Donnelly R, Dickensheets H, Finbloom D. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interf Cytokine Res 1999; 19(6):563-73. (Pubitemid 29331308)
48. Reuter S, Gupta S, Chaturvedi M., Aggarwal B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49(11):1603-16.